BioArctic

BioArctic Equity Ratio

The Equity Ratio of BioArctic (BIOA B.ST) as of Nov 5, 2026 is 76.38 %. In the previous year, Equity Ratio was 80.50 % — a change of -5.12% (lower).

Equity Ratio

76.38 %

YoY

-5.12%

Last updated:

Equity Ratio of BioArctic is 2025 76.38 % . Equity Ratio of BioArctic was 2024 80.50 % . It decreases by -5.12% lower compared to the previous year.

The BioArctic Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
73.06 SEK
Jan 1, 2019
82.35 SEK
Jan 1, 2020
86.38 SEK
Jan 1, 2021
87.85 SEK
Jan 1, 2022
91.60 SEK
Jan 1, 2023
88.24 SEK
Jan 1, 2024
80.50 SEK
Jan 1, 2025
76.38 SEK
The BioArctic Equity Ratio history
YEAREquity RatioYoY
76.38 %-5.12%
80.50 %-8.77%
88.24 %-3.67%
91.60 %+4.27%
87.85 %+1.70%
86.38 %+4.90%
82.35 %+12.72%
73.06 %+30.98%
55.78 %+549.92%
8.58 %-89.61%
82.59 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Equity Ratio of BioArctic is 76.38 % in 2025.

Equity Ratio of BioArctic changed from 80.50 % to 76.38 %, representing a -5.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio BioArctic since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's BioArctic with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BioArctic

All Key Metrics — BioArctic